Is the Partnership of 23andMe and Big Pharma’s British Giant GlaxoSmithKline on the verge of trailblazing cures using the worlds largest database of genetic material or is there a contradicting and weaponized plot to alter our human DNA because of our ignorance and curiosity?

If you’re one of the five million plus customers involved with DNA and ancestry report from 23andMe, “know” that the pharmaceutical giant, GlaxoSmithKline now “owns” your genetic identity code.”

One of the most fascinating subjects on earth has to be the study of genealogy and ancestry. In the last decade, many genetic companies have emerged with the sophisticated prospects of 23andMe.

Yes, there are concerns of cyber-hacking and the stealing of ones personal information, who would have thought that the human DNA would be such an important and profitable commodity.

Let’s play devils advocate and weigh-out the nefarious canvas that rolled out simultaneously in the time frame of genetic technology and the rise of some of the once hidden now revealed crimes of body harvesting, adrenochrome surge, increased abortion issues, cloning and human trafficking.

To the average American, some of these terms and actions were not introduced to our vocabulary, thought processes, or belief systems, one or two decades ago.

Surely there is an increased concern among the masses when it comes to such intimate material collecting, merging with the evolving biotechnology business with patents we know very little or if anything about.

One things for sure, human beings are very curious creatures, we love to solve a good mystery, and in learning the history of where our roots are derived from as well as the various diseases we are storing in our human genetic code, we become empowered, and gain a sense of control over our health and well being.

If the common-man becomes empowered by the “Knowledge” and blessing of genetic technology presented on an individual scale, think of what imagined power awaits the unlimited minds and bank accounts of big pharma drug corporations and their tech partnerships, and their armada of second, and third party partners who intellectually feast upon with the collection of genetic human DNA.

Since the very beginning of it’s launch in 2007, the genomics giant 23andMe till present day has acquired over 5 million specimens contributing to the worlds largest database of DNA. But what will the true price to pay for the Knowledge of biological secrets cost it’s consumers who innocently bought into the service, only seeking to learn about what past nations their inherited their genetic makeup and influence of behavior and health were born.

Over one year ago, the worlds biggest drug-makers GlaxoSmithKline, gained the exclusive rights to 23andMe through their $300 million investment which is a drop in the bucket to what their return will be should they weaponize their gene biotechnology, after all, in 2018, GSK received four year exclusive rights to run analyses to discover new drug targets.

It’s been the alleged decade long plan for 23andMe, who had offered access and it’s science for sale, in the name of the private information of it’s customers without their full disclosure and knowledge as there was interest stirred by over a handful of other biotechnology pharmaceutical corporations.

If you’re one of the five million plus customers involved with DNA and ancestry report from 23andMe, know that the pharmaceutical giant, GlaxoSmithKline now “owns” your genetic identity code.”

It was stated that The “merger” of the two companies will accelerate the development of “novel treatments and cures,” GSK’s CEO wrote in a blog post.

Their narrative reads “23 and Me offers those with an interest in genetics the opportunity to learn more about their personal genetic profile, including information about their genetic ancestry and risks for certain diseases and other personal characteristics.

Individuals can also opt-in to contribute their genetic data to a research database-allowing them to play an important role in creating the next generation of medicines.

With over 5 million customers and over 80% of customers opting in to participate in research, the 23andMe database is now the world’s largest resource of it’s kind and has the potential to offer new insights about diseases and how they can be treated.

About two-thirds of Americans would be more likely to test if they knew their data could be used to make new genetic discoveries and power research into new treatments or cures. Most Americans, about seventy seven percent know that genetics plays a role in the risk for certain diseases and about ninety percent of respondents knew that DNA testing could inform them about their ancestry.

Through the collaboration, our scientists will be able to work with 23andMe scientists to analyze this genetic data to discover potential new starting points for medicines.”

The Partnership between 23andMe and GlaxoSmithKline draws allot of mistrust pertaining to the protection of private information over the valuable commodity of genetic coding.

23andMe grew in numbers by earning the right to tell people what diseases their customers may be predisposed to through the unlocked mystery of their personal DNA, if diseases such as Alzheimer’s, Cancers or Parkinson’s were dormant deep within, not to mention allergies or depression along with 18 other common health conditions, and the ability to see personal reports and what treatments were available to work on their behalf, yet 23andMme received data they would never acquire from any other sources.

Truly the beneficiary’s of 23andMe is GSK who will be using the genetic blueprints of their customers to create new and approved drugs to aid the profits of big pharma and bio tech corporations, don’t be blinded by the thoughts of this information benefiting the holistic communities.

This information was contributed by the 80% of it’s customers who not only shared their genetic data, yet their lifestyle and health information.

“If you read the documents carefully, all the information is there,” says Kayte Spector-Bagdady, a lawyer and bioethics researcher at the University of Michigan who has reviewed 23andMe’s customer policies. “They really do disclose it all. The challenge is that people don’t read it.”

To register a DNA kit on 23andMe, customers are required to accept the company’s privacy policy and terms and conditions, which together disclose what data 23andMe collects, how it’s protected, and how it can be used and shared. Then customers are given the option to participate in 23andMe research.

A lengthy document explains what that entails, and it they click a green box at the bottom saying “I DO GIVE CONSENT,” then the majority of their date, their genetic profile plus any information they enter into surveys or authorize 23andMe to import can be used for research in de-identified and aggregated form.

23andMe customers can however, withdraw their consent at any time with an average of up to 30 days after their requests goes through. Any data shared prior to that date can’t be brought back from any third parties that might be using it.

The conception of deleting an customers data entirely is more impossible, because federal laws require clinical laboratories to keep de-identified DNA test results on fire for a minimum of ten years.

Keep in mind, 23andMe is a commercial enterprise, not a health and wellness company, they make their money off of big data, and human DNA is as big as it gets, their big profit return is fed by the drug discoveries and partnerships from entities of GSK and others.

They are not bound by the same obligations as medical professionals, the corporation doesn’t take an oath to act in the interest of consumers or promote their well being, they are there to make money and profit off of technology enhanced science using the customers genetic material for their own advancement in big pharma and science for sale.

“23andMe originally started out as a Personal Genome Service (PGS) provider. Essentially, they tested customers’ DNA samples for disease markers. Ancestry DNA testing was just a small component of their services. This changed in 2013 when the company was ordered to stop marketing it’s health package until it obtained the required regulatory approval from the FDA. The company had no choice but to pivot fully to ancestry DNA testing. As for the health part of the test, only raw genetic data could be provided. The moratorium from the FDA prevented them from interpreting the data into comprehensible information for customers. 23andMe was finally permitted by the FDA to offer health DNA testing in 2015 and is the only major genealogy DNA test kit that also covers health risks.”

The FDA warns this includes an inherent risk of diagnoses and prescriptions based on false positives or false negatives for certain genetic traits.

23andMe acknowledges the potential for security breaches on it’s website:

“Your genetic data, survey responses, and / or personally identifying information may be stolen in the event of a security breach. In the event of such a breach, if your data are associated with your identity, they may be made public or released to insurance companies which could have a negative effect on your ability to obtain insurance coverage.”

People interested in closing their 23andMe accounts can go here, however, according to the company; “any research involving your data that has already been performed or published prior to our receipt of your request will not be reversed, undone, or withdrawn.”

Let’s not forget that our genetic profile is as valuable, if not more so, than our social security numbers, given to us at birth.

For Further Insight:

https://blog.23andme.com/news/a-note-on-23andmes-new-collaboration-with-gsk/
https://www.gsk.com/en-gb/behind-the-science/innovation/you-me-and-23andme-discovering-new-medicines-through-genetics/
https://mediacenter.23andme.com/press-releases/national-survey-shows-strong-interest-dna-testing/
https://www.gene.com/partners
https://www.topconsumerreviews.com/dna-testing/compare/23-and-me-vs-ancestry.php
https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines/